At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 613 enrolled
Drug / intervention
Lurbinectedin (PM01183) +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
In Brief
A Phase 3 clinical trial evaluating Lurbinectedin (PM01183), Doxorubicin (DOX), and 3 other interventions for Small-cell Lung Cancer. Completed, enrolled 613 participants across 160 sites in 20 countries.
Detailed Summary
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall-cell Lung Cancer
CountriesArgentina, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Italy, Lebanon, Netherlands, Poland, Portugal, Romania, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartAug 2016
Primary CompletionFeb 2020
TodayJul 2026
First PostedOct 2, 2015
Enrollment StartAug 30, 2016
Primary CompletionFeb 24, 2020
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 10.8 years ago
Interventions
Lurbinectedin (PM01183)drug
Doxorubicin (DOX)drug
Cyclophosphamide (CTX)drug
Vincristine (VCR)drug
Topotecandrug